WO2020257169A1 - Polymorphs of a macrocyclic kinase inhibitor - Google Patents

Polymorphs of a macrocyclic kinase inhibitor Download PDF

Info

Publication number
WO2020257169A1
WO2020257169A1 PCT/US2020/037892 US2020037892W WO2020257169A1 WO 2020257169 A1 WO2020257169 A1 WO 2020257169A1 US 2020037892 W US2020037892 W US 2020037892W WO 2020257169 A1 WO2020257169 A1 WO 2020257169A1
Authority
WO
WIPO (PCT)
Prior art keywords
cancer
polymorph form
crystalline polymorph
ret
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2020/037892
Other languages
English (en)
French (fr)
Inventor
Wei Deng
Evan W. ROGERS
Yuelie Lu
Han Zhang
Jing Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Turning Point Therapeutics Inc
Original Assignee
Turning Point Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to KR1020227001994A priority Critical patent/KR20220046549A/ko
Priority to EP20826665.0A priority patent/EP3986413A4/en
Priority to CA3143043A priority patent/CA3143043A1/en
Priority to MX2021015756A priority patent/MX2021015756A/es
Priority to CN202080044953.1A priority patent/CN114025765A/zh
Priority to PE2021002184A priority patent/PE20220135A1/es
Priority to AU2020294627A priority patent/AU2020294627A1/en
Priority to JP2021575515A priority patent/JP2022537385A/ja
Priority to BR112021025786A priority patent/BR112021025786A2/pt
Priority to US17/618,060 priority patent/US20220411439A1/en
Application filed by Turning Point Therapeutics Inc filed Critical Turning Point Therapeutics Inc
Priority to PH1/2021/553174A priority patent/PH12021553174A1/en
Publication of WO2020257169A1 publication Critical patent/WO2020257169A1/en
Priority to IL288982A priority patent/IL288982A/en
Anticipated expiration legal-status Critical
Priority to CONC2022/0000405A priority patent/CO2022000405A2/es
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Definitions

  • This disclosure relates to polymorphs of (3aR,11S,20aS)-7-fluoro-11-methyl- 2,3,3a,12,13,20a-hexahydro-1H,5H-17,19-(metheno)cyclopenta[5,6][1,4]oxazino[3,4- i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one, or a hydrate thereof, that are useful in the treatment of disease, such as cancer, in mammals.
  • This disclosure also relates to compositions including such polymorphs, and to methods of using such compositions in the treatment of diseases, such as cancer, in mammals, especially in humans.
  • [004] is a potent small-molecule multi-target kinase inhibitor showing activity against wild- type and mutant RET, SRC and FGFR1/2.
  • Compound I has properties, including anti-tumor properties, that are pharmacologically mediated through inhibition of tyrosine kinase receptors.
  • Compound I is disclosed in International Patent Publication No. WO 2019/126121 A1
  • Protein kinases are key regulators for cell growth, proliferation and survival.
  • diseases such as cancer, pain, neurological diseases, autoimmune diseases, and
  • the present disclosure provides a crystalline form of (3aR,11S,20aS)-7- fluoro-11-methyl-2,3,3a,12,13,20a-hexahydro-1H,5H-17,19- (metheno)cyclopenta[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2- l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one, or a hydrate thereof.
  • the crystalline polymorph form of (3aR,11S,20aS)-7-fluoro-11- methyl-2,3,3a,12,13,20a-hexahydro-1H,5H-17,19-(metheno)cyclopenta[5,6][1,4]oxazino[3,4- i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one is a hydrate.
  • the crystalline polymorph form of (3aR,11S,20aS)-7-fluoro-11- methyl-2,3,3a,12,13,20a-hexahydro-1H,5H-17,19-(metheno)cyclopenta[5,6][1,4]oxazino[3,4- i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one is anhydrous.
  • the crystalline polymorph form A or D of compound I can be represented by the formula
  • the crystalline polymorph form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2q) of 20.1 ⁇ 0.1. In a further embodiment, the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2q) of 11.3 ⁇ 0.1 and 20.1 ⁇ 0.1. In a further embodiment, the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2q) of 11.3 ⁇ 0.1, 20.1 ⁇ 0.1, and 23.9 ⁇ 0.1.
  • the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2q) of 11.3 ⁇ 0.1, 18.0 ⁇ 0.1, 20.1 ⁇ 0.1, and 23.9 ⁇ 0.1.
  • the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2q) of 10.3 ⁇ 0.1, 11.3 ⁇ 0.1, 18.0 ⁇ 0.1, 20.1 ⁇ 0.1, and 23.9 ⁇ 0.1.
  • the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2q) of 10.3 ⁇ 0.1, 11.3 ⁇ 0.1, 16.6 ⁇ 0.1, 18.0 ⁇ 0.1, 20.1 ⁇ 0.1, and 23.9 ⁇ 0.1.
  • the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2q) of 10.3 ⁇ 0.1, 11.3 ⁇ 0.1, 16.6 ⁇ 0.1, 18.0 ⁇ 0.1, 20.1 ⁇ 0.1, 20.5 ⁇ 0.1, and 23.9 ⁇ 0.1.
  • the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2q) essentially the same as shown in FIG.1.
  • the crystalline polymorph form has a powder X-ray diffraction pattern comprising a peak at diffraction angle (2q) of 18.8 ⁇ 0.1. In a further embodiment, the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2q) of 18.8 ⁇ 0.1 and 20.9 ⁇ 0.1. In a further embodiment, the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2q) of 12.3 ⁇ 0.1, 18.8 ⁇ 0.1, and 20.9 ⁇ 0.1.
  • the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2q) of 12.3 ⁇ 0.1, 18.8 ⁇ 0.1, 19.4 ⁇ 0.1, and 20.9 ⁇ 0.1.
  • the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2q) of 12.3 ⁇ 0.1, 13.1 ⁇ 0.1, 18.8 ⁇ 0.1, 19.4 ⁇ 0.1, and 20.9 ⁇ 0.1.
  • the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2q) of 12.3 ⁇ 0.1, 13.1 ⁇ 0.1, 15.3 ⁇ 0.1, 18.8 ⁇ 0.1, 19.4 ⁇ 0.1, and 20.9 ⁇ 0.1.
  • the crystalline polymorph form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2q) of 9.4 ⁇ 0.1, 12.3 ⁇ 0.1, 13.1 ⁇ 0.1, 15.3 ⁇ 0.1, 18.8 ⁇ 0.1, 19.4 ⁇ 0.1, and 20.9 ⁇ 0.1.
  • the crystalline form has a powder X-ray diffraction pattern comprising peaks at diffraction angles (2q) essentially the same as shown in FIG.3.
  • the present disclosure further provides a pharmaceutical composition
  • a pharmaceutical composition comprising a polymorph form A or form D of Compound I of the formula
  • the present disclosure further provides a capsule comprising pharmaceutical compositions as described herein.
  • the disclosure provides a method of treating disease, especially cancer, in a mammal, including a human, the method comprising administering to the mammal a therapeutically effective amount of polymorph form A or D of (3aR,11S,20aS)-7-fluoro-11- methyl-2,3,3a,12,13,20a-hexahydro-1H,5H-17,19-(metheno)cyclopenta[5,6][1,4]oxazino[3,4- i]pyrazolo[4,3-f]pyrido[3,2-l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one, as described herein, or a pharmaceutical composition comprising polymorph form A or D of (3aR,11S,20aS)- 7-fluoro-11-methyl-2,3,3a,12,13,20a-hexahydro-1H,5H-17,19- (metheno)cyclopenta[5,6
  • the present disclosure provides a method of treating abnormal cell growth in a mammal, including a human, in need of such treatment comprising, administering to said mammal a therapeutically effective amount of the free base polymorph form A or D of Compound I.
  • the abnormal cell growth is mediated by at least one genetically altered tyrosine kinase.
  • the abnormal cell growth is mediated by RET, SRC, FGFR1/2 or a combination thereof. In some embodiments, the abnormal cell growth is mediated by wild- type or mutant RET. In some embodiments, the abnormal cell growth is mediated by wild-type or mutant SRC. In some embodiments, the abnormal cell growth is mediated by wild-type or mutant FGFR1/2.
  • the present disclosure provides a method of treating abnormal cell growth in a patient in need of such treatment comprising, administering a therapeutically effective amount of Compound I. In some embodiments, the present disclosure provides a method of treating abnormal cell growth in a patient in need of such treatment comprising, administering a therapeutically effective amount of the free base polymorph form A or D of Compound I. In some embodiments, the abnormal cell growth is cancer mediated by a genetically altered RET.
  • the abnormal cell growth is cancer mediated by a genetically altered RET comprising at least one point mutation selected from the group consisting of A883F, E762Q, G691S, L790F, M918T, R749T, R813Q, S891A, S904A, S904F, V778I, V804L, V804M, Y791F, and Y806H.
  • the present disclosure provides a method of treating abnormal cell growth in a patient in need of such treatment comprising, administering a therapeutically effective amount of Compound I. In some embodiments, the present disclosure provides a method of treating abnormal cell growth in a patient in need of such treatment comprising, administering a therapeutically effective amount of the free base polymorph form A or D of Compound I. In some embodiments, the abnormal cell growth is cancer mediated by a fusion protein comprising a fragment of a protein encoded by an RET gene and a fragment of a protein which can form coiled-coil interaction to facilitate the protein dimerization or oligomerization.
  • the abnormal cell growth is cancer mediated by a fusion protein comprising a fragment of a protein encoded by an RET gene and a fragment of a protein encoded by a gene selected from the group consisting of KIF5B, CCDC6, NCOA4, TRIM24, TRIM33, PRKAR1A, GOLGA5, KTN1, ERC1, MBD1, and TRIM27.
  • the fusion protein comprises a fragment of a protein encoded by an RET gene and a fragment of a protein encoded by a KIF5B gene.
  • the genetically altered RET is a KIF5B-RET, CCDC6-RET, NCOA4-RET, TRIM24-RET, TRIM33-RET, PRKAR1A -RET, GOLGA5-RET, KTN1-RET, ERC1-RET, MBD1-RET, or TRIM27-RET fusion protein.
  • the genetically altered RET is a KIF5B-RET fusion protein.
  • the KIF5B-RET fusion protein is a wild-type protein.
  • the KIF5B-RET fusion protein comprises at least one resistance mutation.
  • the KIF5B-RET fusion protein comprises at least one gate keeper resistance mutation.
  • the KIF5B-RET fusion protein comprises at least one solvent front resistance mutation. In some embodiments, the KIF5B-RET fusion protein comprises at least one mutation selected from the group consisting of A883F, E762Q, G691S, L790F, M918T, R749T, R813Q, S891A, S904A, S904F, V778I, V804L, V804M, Y791F, Y806H , V804M, G810R, G810C, and G810S. In some embodiments, the KIF5B-RET fusion protein comprises at least one mutation selected from the group consisting of V804M, G810R, G810C, and G810S.
  • the abnormal cell growth is cancer.
  • the cancer is selected from the group consisting of lung cancer, non-small cell lung cancer, small cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, hepatocellular carcinoma, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease gastric and esophago-gastric cancers, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, such as anaplastic large cell lymphoma
  • [046] 23 A method of treating disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of the crystalline polymorph form of any one of clauses 1 to 21.
  • cancer is selected from the groups consisting of lung cancer, non-small cell lung cancer, small cell lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, hepatocellular carcinoma, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, gastric and esophago-gastric cancers, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, such as anaplastic large cell lymphoma, cancer of the bladder, cancer
  • RET is a KIF5B-RET, CCDC6-RET, NCOA4-RET, TRIM24-RET, TRIM33-RET, PRKAR1A -RET, GOLGA5-RET, KTN1-RET, ERC1-RET, MBD1-RET, or TRIM27-RET fusion protein.
  • the KIF5B-RET fusion protein comprises at least one mutation selected from the group consisting of A883F, E762Q, G691S, L790F, M918T, R749T, R813Q, S891A, S904A, S904F, V778I, V804L, V804M, Y791F, Y806H , V804M, G810R, G810C, and G810S.
  • abnormal cell growth refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition).
  • the term“treating” means reversing, alleviating, inhibiting the progress of (i.e., curative treatment), or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition.
  • treatment refers to the act of treating as “treating” as defined immediately above.
  • Preventative treatment is meant to indicate a postponement of development of a disease, a symptom of a disease, or medical condition, suppressing symptoms that may appear, or reducing the risk of developing or recurrence of a disease or symptom.
  • “Curative” treatment includes reducing the severity of or suppressing the worsening of an existing disease, symptom, or condition.
  • treatment includes ameliorating or preventing the worsening of existing disease symptoms, preventing additional symptoms from occurring, ameliorating or preventing the underlying systemic causes of symptoms, inhibiting the disorder or disease, e.g., arresting the development of the disorder or disease, relieving the disorder or disease, causing regression of the disorder or disease, relieving a condition caused by the disease or disorder, or stopping the symptoms of the disease or disorder.
  • subject refers to a mammalian patient in need of such treatment, such as a human.
  • the term“essentially the same” with reference to X-ray diffraction peak positions means that typical peak position and intensity variability are taken into account.
  • the peak positions (2q) will show some inter- apparatus variability, typically as much as 0.1°.
  • relative peak intensities will show inter-apparatus variability as well as variability due to degree of crystallinity, preferred orientation, prepared sample surface, and other factors known to those skilled in the art, and should be taken as qualitative measures only.
  • FIG.1 shows a powder X-ray diffraction pattern of the crystalline form of
  • FIG.2 shows a differential scanning calorimetry (DSC) thermogram of the crystalline form of (3aR,11S,20aS)-7-fluoro-11-methyl-2,3,3a,12,13,20a-hexahydro-1H,5H-17,19- (metheno)cyclopenta[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2- l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one monohydrate, polymorph form A.
  • DSC differential scanning calorimetry
  • FIG.3 shows a powder X-ray diffraction pattern of the crystalline form of
  • FIG.4 shows a differential scanning calorimetry (DSC) thermogram of the crystalline form of (3aR,11S,20aS)-7-fluoro-11-methyl-2,3,3a,12,13,20a-hexahydro-1H,5H-17,19- (metheno)cyclopenta[5,6][1,4]oxazino[3,4-i]pyrazolo[4,3-f]pyrido[3,2- l][1,4,8,10]oxatriazacyclotridecin-14(11H)-one (solvent-free and anhydrous), polymorph form D.
  • DSC differential scanning calorimetry
  • FIG.5A is a chart showing the activity of Compound I, Loxo-292, and BLU-667 in Ba/F3 KIF5B-RET cell proliferation assay.
  • FIG.5B is a chart showing the activity of Compound I, Loxo-292, and BLU-667 in Ba/F3 KIF5B-RET cell proliferation assay.
  • FIG.6A are gel images the effect of Compound I on RET-G810C phosphorylation at residue Y905 in Ba/F3 engineered cells at various concentrations in nM.
  • FIG.6B are gel images the effect of LOXO-292 on RET-G810C phosphorylation at residue Y905 in Ba/F3 engineered cells at various concentrations in nM.
  • the compounds and pharmaceutical compositions of the invention specifically target tyrosine receptor kinases, in particular RET, SRC or FGFR1/2.
  • these compounds and pharmaceutical compositions can be used to prevent, reverse, slow, or inhibit the activity of one or more of these kinases.
  • methods of treatment disease mediated by one or more receptor tyrosine kinase are described herein.
  • Exemplary diseases include cancer, pain, neurological diseases, autoimmune diseases, and inflammation.
  • cancer includes but is not limited to lung cancer, such as non-small cell lung cancer, small cell lung cancer, and the like, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, hepatocellular carcinoma, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, gastric and esophago-gastric cancers, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic
  • the abnormal cell growth is mediated by RET, SRC, FGFR1/2 or a combination thereof. In some embodiments, the abnormal cell growth is mediated by wild- type or mutant RET. In some embodiments, the abnormal cell growth is mediated by wild-type or mutant SRC. In some embodiments, the abnormal cell growth is mediated by wild-type or mutant FGFR1/2.
  • the present disclosure provides a method of treating abnormal cell growth in a patient in need of such treatment comprising, administering a therapeutically effective amount of Compound I. In some embodiments, the present disclosure provides a method of treating abnormal cell growth in a patient in need of such treatment comprising, administering a therapeutically effective amount of the free base polymorph form A or D of Compound I. In some embodiments, the abnormal cell growth is cancer mediated by a genetically altered RET.
  • the abnormal cell growth is cancer mediated by a genetically altered RET comprising at least one point mutation selected from the group consisting of A883F, E762Q, G691S, L790F, M918T, R749T, R813Q, S891A, S904A, S904F, V778I, V804L, V804M, Y791F, and Y806H.
  • the present disclosure provides a method of treating abnormal cell growth in a patient in need of such treatment comprising, administering a therapeutically effective amount of Compound I.
  • the present disclosure provides a method of treating abnormal cell growth in a patient in need of such treatment comprising, administering a therapeutically effective amount of the free base polymorph form A or D of Compound I.
  • the abnormal cell growth is cancer mediated by a fusion protein comprising a fragment of a protein encoded by an RET gene and a fragment of a protein which can form coiled-coil interaction to facilitate the protein dimerization or oligomerization.
  • the abnormal cell growth is cancer mediated by a fusion protein comprising a fragment of a protein encoded by an RET gene and a fragment of a protein encoded by a gene selected from the group consisting of KIF5B, CCDC6, NCOA4, TRIM24, TRIM33, PRKAR1A, GOLGA5, KTN1, ERC1, MBD1, and TRIM27.
  • the fusion protein comprises a fragment of a protein encoded by an RET gene and a fragment of a protein encoded by a KIF5B gene.
  • the genetically altered RET is a KIF5B-RET, CCDC6-RET, NCOA4-RET, TRIM24-RET, TRIM33-RET, PRKAR1A -RET, GOLGA5-RET, KTN1-RET, ERC1-RET, MBD1-RET, or TRIM27-RET fusion protein.
  • the genetically altered RET is a KIF5B-RET fusion protein.
  • the KIF5B-RET fusion protein is a wild-type protein.
  • the KIF5B-RET fusion protein comprises at least one resistance mutation.
  • the KIF5B-RET fusion protein comprises at least one gate keeper resistance mutation.
  • the KIF5B-RET fusion protein comprises at least one solvent front resistance mutation. In some embodiments, the KIF5B-RET fusion protein comprises at least one mutation selected from the group consisting of A883F, E762Q, G691S, L790F, M918T, R749T, R813Q, S891A, S904A, S904F, V778I, V804L, V804M, Y791F, Y806H , V804M, G810R, G810C, and G810S. In some embodiments, the KIF5B-RET fusion protein comprises at least one mutation selected from the group consisting of V804M, G810R, G810C, and G810S.
  • Pain includes, for example, pain from any source or etiology, including cancer pain, pain from chemotherapeutic treatment, nerve pain, pain from injury, or other sources.
  • autoimmune diseases include, for example, rheumatoid arthritis, Sjogren syndrome, Type I diabetes, and lupus.
  • exemplary neurological diseases include Alzheimer’s Disease, Parkinson’s Disease, Amyotrophic lateral sclerosis, and Huntington’s disease.
  • methods of treating inflammatory diseases of inflammation comprising administering a therapeutically effective amount of a crystalline polymorph form A or D of Compound I.
  • inflammatory diseases include atherosclerosis, allergy, and inflammation from infection or injury.
  • an“effective amount” means an amount or dose sufficient to generally bring about the desired therapeutic benefit in subjects needing such treatment.
  • Effective amounts or doses of the compounds of the invention may be ascertained by routine methods, such as modeling, dose escalation, or clinical trials, taking into account routine factors, e.g., the mode or route of administration or drug delivery, the pharmacokinetics of the agent, the severity and course of the infection, the subject’s health status, condition, and weight, and the judgment of the treating physician.
  • An exemplary dose is in the range of about from about 0.1 mg to 1 g daily, or about 1 mg to 50 mg daily, or about 50 to 250 mg daily, or about 250 mg to 1 g daily.
  • the total dosage may be given in single or divided dosage units (e.g., BID, TID, QID).
  • the dose may be adjusted for preventative or maintenance treatment.
  • the dosage or the frequency of administration, or both may be reduced as a function of the symptoms, to a level at which the desired therapeutic or prophylactic effect is maintained.
  • treatment may cease.
  • Patients may, however, require intermittent treatment on a long-term basis upon any recurrence of symptoms. Patients may also require chronic treatment on a long-term basis.
  • compositions of the present disclosure also relates to pharmaceutical compositions comprising the free base polymorph form A or D of Compound I described herein.
  • Pharmaceutical compositions of the present disclosure may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository.
  • the pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages.
  • the pharmaceutical composition may include conventional pharmaceutically-acceptable excipients.
  • pharmaceutical compositions described herein may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.
  • a pharmaceutically-acceptable excipient is a substance that is non-toxic and otherwise biologically suitable for administration to a subject. Such excipients facilitate administration of the compounds described herein and are compatible with the active ingredient.
  • examples of pharmaceutically-acceptable excipients include stabilizers, lubricants, surfactants, diluents, anti- oxidants, binders, coloring agents, bulking agents, emulsifiers, or taste-modifying agents.
  • pharmaceutical compositions according to the invention are sterile compositions. Pharmaceutical compositions may be prepared using compounding techniques known or that become available to those skilled in the art.
  • compositions are also contemplated by the invention, including compositions that are in accord with national and local regulations governing such compositions.
  • compositions and compounds described herein may be formulated as solutions, emulsions, suspensions, or dispersions in suitable pharmaceutical solvents or carriers, or as pills, tablets, lozenges, suppositories, sachets, dragees, granules, powders, powders for reconstitution, or capsules along with solid carriers according to conventional methods known in the art for preparation of various dosage forms.
  • suitable pharmaceutical solvents or carriers or as pills, tablets, lozenges, suppositories, sachets, dragees, granules, powders, powders for reconstitution, or capsules along with solid carriers according to conventional methods known in the art for preparation of various dosage forms.
  • compositions of the invention may be administered by a suitable route of delivery, such as oral, parenteral, rectal, nasal, topical, or ocular routes, or by inhalation.
  • a suitable route of delivery such as oral, parenteral, rectal, nasal, topical, or ocular routes, or by inhalation.
  • the compositions are formulated for intravenous or oral administration.
  • the compounds the invention may be provided in a solid form, such as a tablet or capsule, or as a solution, emulsion, or suspension.
  • the compounds of the invention may be formulated to yield a dosage of, e.g., from about 0.1 mg to 1 g daily, or about 1 mg to 50 mg daily, or about 50 to 250 mg daily, or about 250 mg to 1 g daily.
  • Oral tablets may include the active ingredient(s) mixed with compatible pharmaceutically acceptable excipients such as diluents, disintegrating agents, binding agents, lubricating agents, sweetening agents, flavoring agents, coloring agents and preservative agents.
  • Suitable inert fillers include sodium and calcium carbonate, sodium and calcium phosphate, lactose, starch, sugar, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, and the like.
  • Exemplary liquid oral excipients include ethanol, glycerol, water, and the like.
  • Starch polyvinyl-pyrrolidone (PVP), sodium starch glycolate,
  • microcrystalline cellulose, and alginic acid are exemplary disintegrating agents.
  • Binding agents may include starch and gelatin.
  • the lubricating agent if present, may be magnesium stearate, stearic acid, or talc. If desired, the tablets may be coated with a material such as glyceryl monostearate or glyceryl distearate to delay absorption in the gastrointestinal tract, or may be coated with an enteric coating.
  • Capsules for oral administration include hard and soft gelatin capsules.
  • active ingredient(s) may be mixed with a solid, semi-solid, or liquid diluent.
  • Soft gelatin capsules may be prepared by mixing the active ingredient with water, an oil, such as peanut oil or olive oil, liquid paraffin, a mixture of mono and di-glycerides of short chain fatty acids, polyethylene glycol 400, or propylene glycol.
  • Liquids for oral administration may be in the form of suspensions, solutions, emulsions, or syrups, or may be lyophilized or presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid compositions may optionally contain:
  • suspending agents for example, sorbitol, methyl cellulose, sodium alginate, gelatin, hydroxyethylcellulose, carboxymethylcellulose, aluminum stearate gel and the like
  • non-aqueous vehicles e.g., oil (for example, almond oil or fractionated coconut oil), propylene glycol, ethyl alcohol, or water
  • preservatives for example, methyl or propyl p-hydroxybenzoate or sorbic acid
  • wetting agents such as lecithin; and, if desired, flavoring or coloring agents.
  • the agents of the invention may be provided in sterile aqueous solutions or suspensions, buffered to an appropriate pH and isotonicity or in parenterally acceptable oil.
  • Suitable aqueous vehicles include Ringer's solution and isotonic sodium chloride.
  • Such forms may be presented in unit-dose form such as ampoules or disposable injection devices, in multi- dose forms such as vials from which the appropriate dose may be withdrawn, or in a solid form or pre-concentrate that can be used to prepare an injectable formulation.
  • Illustrative infusion doses range from about 1 to 1000 mg/kg/minute of agent admixed with a pharmaceutical carrier over a period ranging from several minutes to several days.
  • inventive pharmaceutical compositions may be administered using, for example, a spray formulation also containing a suitable carrier.
  • inventive compositions may be formulated for rectal administration as a suppository.
  • the compounds of the present invention are preferably formulated as creams or ointments or a similar vehicle suitable for topical administration.
  • the inventive compounds may be mixed with a pharmaceutical carrier at a concentration of about 0.1% to about 10% of drug to vehicle.
  • Another mode of administering the agents of the invention may utilize a patch formulation to effect transdermal delivery
  • inventive compounds described herein may be used in pharmaceutical compositions or methods in combination with one or more additional active ingredients in the treatment of the diseases and disorders described herein.
  • Further additional active ingredients include other therapeutics or agents that mitigate adverse effects of therapies for the intended disease targets. Such combinations may serve to increase efficacy, ameliorate other disease symptoms, decrease one or more side effects, or decrease the required dose of an inventive compound.
  • the additional active ingredients may be administered in a separate pharmaceutical composition from a compound of the present invention or may be included with a compound of the present invention in a single pharmaceutical composition.
  • the additional active ingredients may be administered simultaneously with, prior to, or after administration of a compound of the present invention.
  • Combination agents include additional active ingredients are those that are known or discovered to be effective in treating the diseases and disorders described herein, including those active against another target associated with the disease.
  • compositions and formulations of the invention, as well as methods of treatment can further comprise other drugs or pharmaceuticals, e.g., other active agents useful for treating or palliative for the target diseases or related symptoms or conditions.
  • additional such agents include, but are not limited to, kinase inhibitors, such as EGFR inhibitors (e.g., erlotinib, gefitinib), Raf inhibitors (e.g., vemurafenib), VEGFR inhibitors (e.g., sunitinib), ALK inhibitors (e.g., crizotinib) standard chemotherapy agents such as alkylating agents, antimetabolites, anti-tumor antibiotics, topoisomerase inhibitors, platinum drugs, mitotic inhibitors, antibodies, hormone therapies, or corticosteroids.
  • suitable combination agents include anti-inflammatories such as NSAIDs.
  • compositions of the invention may additional comprise one or more of such active agents, and methods of treatment may additionally comprise administering an effective amount of one or more of such active agents.
  • EXAMPLES [0107] The examples and preparations provided below further illustrate and exemplify particular aspects of embodiments of the disclosure. It is to be understood that the scope of the present disclosure is not limited in any way by the scope of the following examples. [0108] Abbreviations
  • Step 1 To a solution of B-1 (454 mg, 1.49 mmol) and A-5 (358 mg, 1.49 mmol) in t- BuOH (5.0 mL) was added Hunig’s base (963 mg, 7.45 mmol, 1.30 mL). The mixture was heated to 105 °C for 17 hr. The reaction was cooled and concentrated under reduced pressure. Flash chromatography (ISCO system, silica (12 g), 10-40% ethyl acetate in hexane) provided 5- 1 (292 mg, 38% yield).
  • Step 2 To a solution of 5-1 (18.8 mg, 37 ⁇ mol) in DMF (3 mL) was added KOt-Pent (1.7 M, 65 ⁇ L) in toluene. The reaction stirred at room temperature for 20 hours. The reaction was cooled to -20 °C and quenched with saturated NH4Cl sol. (5 mL) then extracted with DCM (3 x 10 mL). Combined extracts were dried with Na 2 SO 4 and concentrated under reduced pressure. Flash chromatography (ISCO system, silica (12 g), 0-5% methanol in
  • Step 3 To a solution of 5-2 (6.2 mg, 14.5 ⁇ mol) in EtOH (4 mL) was added aqueous HCl solution (4.0 M, 3.0 mL) in 1,4-dioxane. The mixture was heated at 70 °C for 6 hours. The mixture was cooled,concentrated under reduced pressure, and dried under high vacuum to provide crude 5-3. Compound was used as is. [0117] Step 4.
  • Step 5 To a solution of 5-4 (6.1 mg, 10.7 ⁇ mol) in MeOH (3 mL) and THF (1 mL) at ambient temperature was added aqueous LiOH solution (2.0 M, 1.0 mL). The mixture was heated at 60 °C for 16 hr, cooled to -20 °C then quenched with aqueous HCl solution (2.0 M) to acidic. The mixture was extracted with DCM (3 x 5 mL), dried with Na 2 SO 4, concentrated under reduced pressure, and dried under high vacuum. The crude material was dissolved in DCM (4 mL) followed by addition of HCl in 1,4-dioxane (4 M, 3 mL).
  • Compound A-5 was prepared according to General Method A using 5-Fluoro-2- methoxynicotinaldehyde in step 2.
  • FT-Raman was carried out on a sample of Compound I, crystalline polymorph form A using a Bruker MultiRAM FT-Raman system with a near infrared Nd:YAG laser operating at 1064 nm and a liquid nitrogen-cooled germanium detector. 64 scans with a resolution of 2 cm -1 were accumulated in the range from 3500 to 50 cm -1 . Laser power were 300 mW. Only data above 100 cm -1 were evaluated due to filter cutoff effects.
  • the sample of Compound I, crystalline polymorph form A showed absorptions as in Table 3:
  • reaction buffer 20 mM Hepes pH 7.5, 10 mM MgCl 2 , 1 mM EGTA, 0.02% Brij35, 0.02 mg/ml BSA, 0.1 mM Na3VO4, 2 mM DTT, 1% DMSO.
  • Compounds were delivered into the reaction, followed ⁇ 20 minutes later by addition of a mixture of ATP (Sigma, St.
  • the EML4-ALK gene (variant 1) was synthesized at GenScript and cloned into pCDH- CMV-MCS-EF1-Puro plasmid (System Biosciences, Inc).
  • Ba/F3-EML4-ALK wild type were generated by transducing Ba/F3 cells with lentivirus containing EML4-ALK wide type. Stable cell lines were selected by puromycin treatment, followed by IL-3 withdrawal. Briefly, 5X10 6 Ba/F3 cells were transduced with lentivirus supernatant in the presence of 8 ⁇ g/mL protamine sulfate. The transduced cells were subsequently selected with 1 ⁇ g/mL puromycin in the presence of IL3-containing medium RPMI1640, plus 10% FBS. After 10-12 days of selection, the surviving cells were further selected for IL3 independent growth.
  • KIF5B-RET gene was synthesized at GenScript and cloned into pCDH-CMV- MCS-EF1-Puro plasmid (System Biosciences, Inc). KIF5B-RET point mutation V804M and G810C were generated at GenScript by PCR and confirmed by sequencing.
  • Ba/F3-KIF5B-RET wild type and mutant were generated by transducing Ba/F3 cells with lentivirus containing KIF5B-RET wide type or mutant. Stable cell lines were selected by puromycin treatment, followed by IL-3 withdrawal.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PCT/US2020/037892 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor Ceased WO2020257169A1 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
BR112021025786A BR112021025786A2 (pt) 2019-06-19 2020-06-16 Polimorfos de um inibidor de quinase macrocíclico
CA3143043A CA3143043A1 (en) 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor
MX2021015756A MX2021015756A (es) 2019-06-19 2020-06-16 Polimorfos de un inhibidor de cinasas macrociclicas.
CN202080044953.1A CN114025765A (zh) 2019-06-19 2020-06-16 巨环激酶抑制剂的多晶型
PE2021002184A PE20220135A1 (es) 2019-06-19 2020-06-16 Polimorfos de un inhibidor de cinasas macrociclicas
AU2020294627A AU2020294627A1 (en) 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor
JP2021575515A JP2022537385A (ja) 2019-06-19 2020-06-16 大環状キナーゼ阻害剤の多形
KR1020227001994A KR20220046549A (ko) 2019-06-19 2020-06-16 거대고리 카이네이스 억제제의 다형체
EP20826665.0A EP3986413A4 (en) 2019-06-19 2020-06-16 POLYMORPHS OF A MACROCYCLIC KINASE INHIBITOR
US17/618,060 US20220411439A1 (en) 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor
PH1/2021/553174A PH12021553174A1 (en) 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor
IL288982A IL288982A (en) 2019-06-19 2021-12-14 Macrocyclic kinase inhibitor polymorphs
CONC2022/0000405A CO2022000405A2 (es) 2019-06-19 2022-01-19 Polimorfos de un inhibidor de cinasas macrocíclicas

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962863493P 2019-06-19 2019-06-19
US62/863,493 2019-06-19
US202062959940P 2020-01-11 2020-01-11
US62/959,940 2020-01-11
US202063036102P 2020-06-08 2020-06-08
US63/036,102 2020-06-08

Publications (1)

Publication Number Publication Date
WO2020257169A1 true WO2020257169A1 (en) 2020-12-24

Family

ID=74040102

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2020/037892 Ceased WO2020257169A1 (en) 2019-06-19 2020-06-16 Polymorphs of a macrocyclic kinase inhibitor

Country Status (15)

Country Link
US (1) US20220411439A1 (cg-RX-API-DMAC7.html)
EP (1) EP3986413A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022537385A (cg-RX-API-DMAC7.html)
KR (1) KR20220046549A (cg-RX-API-DMAC7.html)
CN (1) CN114025765A (cg-RX-API-DMAC7.html)
AU (1) AU2020294627A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021025786A2 (cg-RX-API-DMAC7.html)
CA (1) CA3143043A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022000405A2 (cg-RX-API-DMAC7.html)
IL (1) IL288982A (cg-RX-API-DMAC7.html)
MX (1) MX2021015756A (cg-RX-API-DMAC7.html)
PE (1) PE20220135A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021553174A1 (cg-RX-API-DMAC7.html)
TW (1) TW202115090A (cg-RX-API-DMAC7.html)
WO (1) WO2020257169A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113336774B (zh) * 2021-06-25 2023-05-23 江南大学 作为trk抑制剂的取代的手性二芳基大环化合物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180186813A1 (en) * 2015-07-02 2018-07-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
US20180194777A1 (en) * 2015-07-06 2018-07-12 Tp Therapeutics, Inc. Diaryl macrocycle polymorph
WO2019012093A1 (en) * 2017-07-14 2019-01-17 Glaxosmithkline Intellectual Property Development Limited INHIBITORS OF REACTION KINASE 2 RICH IN LEUCINE
WO2019126121A1 (en) 2017-12-19 2019-06-27 Tp Therapeutics, Inc. Macrocyclic compounds for treating disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015112806A2 (en) * 2014-01-24 2015-07-30 Tp Therapeutics, Inc. Diaryl macrocycles as modulators of protein kinases
WO2017015367A1 (en) * 2015-07-21 2017-01-26 Tp Therapeutics, Inc. Chiral diaryl macrocycles and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180186813A1 (en) * 2015-07-02 2018-07-05 Tp Therapeutics, Inc. Chiral diaryl macrocycles as modulators of protein kinases
US20180194777A1 (en) * 2015-07-06 2018-07-12 Tp Therapeutics, Inc. Diaryl macrocycle polymorph
WO2019012093A1 (en) * 2017-07-14 2019-01-17 Glaxosmithkline Intellectual Property Development Limited INHIBITORS OF REACTION KINASE 2 RICH IN LEUCINE
WO2019126121A1 (en) 2017-12-19 2019-06-27 Tp Therapeutics, Inc. Macrocyclic compounds for treating disease

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1975, MACK PUBLISHING COMPANY
ANASTASSIADIS T ET AL., NAT BIOTECHNOL., vol. 29, 2011, pages 1039
MANNING, G. ET AL., SCIENCE, vol. 298, 2002, pages 1912 - 1934
SAWYERS, C., NATURE, vol. 432, 2004, pages 294 - 297
See also references of EP3986413A4

Also Published As

Publication number Publication date
PH12021553174A1 (en) 2022-08-01
MX2021015756A (es) 2022-01-27
AU2020294627A1 (en) 2022-02-17
IL288982A (en) 2022-02-01
PE20220135A1 (es) 2022-01-27
JP2022537385A (ja) 2022-08-25
BR112021025786A2 (pt) 2022-02-01
KR20220046549A (ko) 2022-04-14
CA3143043A1 (en) 2020-12-24
TW202115090A (zh) 2021-04-16
EP3986413A4 (en) 2023-06-14
CN114025765A (zh) 2022-02-08
CO2022000405A2 (es) 2022-04-29
US20220411439A1 (en) 2022-12-29
EP3986413A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
US12187739B2 (en) Diaryl macrocycle polymorph
KR102806778B1 (ko) Erbb 수용체 억제제
US11142533B2 (en) Macrocycles for use in treating disease
US20220411439A1 (en) Polymorphs of a macrocyclic kinase inhibitor
CN118652239A (zh) 一类egfr别构抑制剂的合成及其用途
CN120383584A (zh) 喹唑啉酮衍生物及其制备方法和用途
HK40059224A (en) Diaryl macrocycle polymorph and method for preparing the same
HK40059224B (en) Diaryl macrocycle polymorph and method for preparing the same
HK1254492B (en) Diaryl macrocycle polymorph
HK40046084B (en) Erbb receptor inhibitors
HK40046084A (en) Erbb receptor inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20826665

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3143043

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021575515

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021025786

Country of ref document: BR

WWE Wipo information: entry into national phase

Ref document number: NC2022/0000405

Country of ref document: CO

ENP Entry into the national phase

Ref document number: 2020826665

Country of ref document: EP

Effective date: 20220119

ENP Entry into the national phase

Ref document number: 112021025786

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20211220

ENP Entry into the national phase

Ref document number: 2020294627

Country of ref document: AU

Date of ref document: 20200616

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: NC2022/0000405

Country of ref document: CO

WWW Wipo information: withdrawn in national office

Ref document number: 2020826665

Country of ref document: EP

WWR Wipo information: refused in national office

Ref document number: NC2022/0000405

Country of ref document: CO

WWW Wipo information: withdrawn in national office

Ref document number: 288982

Country of ref document: IL